Author:
Zirlik Katja,Duyster Justus
Publisher
Springer International Publishing
Reference76 articles.
1. Andersen JB, Spee B, Blechacz BR et al (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142(4):1021–1031. e1015
2. Baselga J, Tripathy D, Mendelsohn J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 14(3):737–744
3. Bendell JC, Powderly JD, Hanyoung Lieu C, Gail Eckhardt S, Hurwitz H, Hochster HS, Murphy JE, Funke RO, Rossi C, Wallin J, Waterkamp D, Pishvaian MJ (2015) Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 33:2015. (suppl 3; abstr 704)
4. Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(29):4536–4541
5. Ciardiello F, Bianco R, Damiano V et al (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6(9):3739–3747